Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Principal inclusion criteria : * Subjects with histologically- or cytologically-documented NSCLC * Locally advanced, unresectable (Stage III) NSCLC * World Health Organisation (WHO) performance status 0-1 * At least one measurable lesion, not previously irradiated * Must have a life expectancy of at least 12 weeks at randomization Principal exclusion criteria : * Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs. * Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines. * History of allogeneic organ transplantation * Active or prior documented autoimmune or inflammatory disorders * Uncontrolled intercurrent illness * History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency * Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus * Mixed small cell and NSCLC histology * Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling * Known allergy or hypersensitivity to any of the IPs or any of the IP excipients. * Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.